98%
921
2 minutes
20
Background: Survival of Wilms tumor (WT) is > 90% in high-resource settings but < 30% in low-resource settings. Adapting a standardized surgical approach to WT is challenging in low-resource settings, but a local control strategy is crucial to improving outcomes.
Objective: Provide resource-sensitive recommendations for the surgical management of WT.
Methods: We performed a systematic review of PubMed and EMBASE through July 7, 2020, and used the GRADE approach to assess evidence and recommendations.
Recommendations: Initiation of treatment should be expedited, and surgery should be done in a high-volume setting. Cross-sectional imaging should be done to optimize preoperative planning. For patients with typical clinical features of WT, biopsy should not be done before chemotherapy, and neoadjuvant chemotherapy should precede surgical resection. Also, resection should include a large transperitoneal laparotomy, adequate lymph node sampling, and documentation of staging findings. For WT with tumor thrombus in the inferior vena cava, neoadjuvant chemotherapy should be given before en bloc resection of the tumor and thrombus and evaluation for viable tumor thrombus. For those with bilateral WT, neoadjuvant chemotherapy should be given for 6-12 weeks. Neither routine use of complex hilar control techniques during nephron-sparing surgery nor nephron-sparing resection for unilateral WT with a normal contralateral kidney is recommended. When indicated, postoperative radiotherapy should be administered within 14 days of surgery. Post-chemotherapy pulmonary oligometastasis should be resected when feasible, if local protocols allow omission of whole-lung irradiation in patients with nonanaplastic histology stage IV WT with pulmonary metastasis without evidence of extrapulmonary metastasis.
Conclusion: We provide evidence-based recommendations for the surgical management of WT, considering the benefits/risks associated with limited-resource settings.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pbc.29906 | DOI Listing |
Food Sci Nutr
September 2025
Department of Nutrition Sciences, School of Health Larestan University of Medical Sciences Iran.
Chronic myeloid leukemia (CML), a myeloproliferative neoplasm, is characterized by the fusion gene, which results in constitutive tyrosine kinase activity. While tyrosine kinase inhibitors (TKIs) have significantly improved CML outcomes, resistance and the persistence of leukemic stem cells remain major clinical challenges. Curcumin, a natural polyphenol derived from , has demonstrated potential anticancer properties.
View Article and Find Full Text PDFClin Chim Acta
September 2025
Department of Physiology, University of Louisville, Louisville 40202 KY, USA. Electronic address:
Diabetic nephropathy (DN) is a major cause of end-stage renal disease, with podocyte injury representing an early pathogenic event. Conventional biomarkers such as albuminuria and eGFR identify renal damage only at advanced stages, limiting opportunities for timely intervention. Wilms' Tumor 1 (WT1), a podocyte-specific transcription factor, has emerged as a sensitive marker of early glomerular stress.
View Article and Find Full Text PDFGen Physiol Biophys
September 2025
The Second Department of Nephrology, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
Diabetic nephropathy (DN) is a major complication of diabetes, imposing substantial socioeconomic and public health challenges. N6-methyladenosine (m6A) modification, a prevalent epigenetic mechanism, influences cellular processes and disease progression. Wilms' tumor 1-associating protein (WTAP), an m6A methyltransferase subunit, was investigated for its role in DN.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Pediatric Surgery, Qilu Hospital of Shandong University, Jinan, China.
Urology
September 2025
Atrium Health Carolinas Medical Center, Department of Urology, 1225 Harding Place Charlotte Unit 3100, NC 28204; Atrium Health Levine Children's Hospital, 1001 Blythe Blvd Suite 4100a Charlotte, NC 28204.
Denys Drash syndrome (DDS) results from a mutation in the WT1 tumor suppressor gene manifesting early in childhood. The classic presentation is characterized by early end stage renal disease (ESRD), differences of sexual differentiation (DSD), and high risk of Wilms tumor (WT). Management varies based on individual patient presentations.
View Article and Find Full Text PDF